BRCA1 and hepatocellular carcinoma: The hybrid ligands were screened for their inhibitory effects on the viability of six different cancer cell lines, comprising two luminal (ZR75-1, MCF-7), one HER2+ (MDA-MB-453), and three TNBC lines without (MDA-MB-468) and with (HCC-1937, MDA-MD-436) pathogenic BRCA1 mutations (Table 1) [22,23].